Prostate cancer
Conditions
Interventions
Patients are treated with image-guided hypo fractionated IMRT/VMAT (67.6Gy/26fx.) using fiducial gold markers in the prostate.
Sponsors
Tohoku University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Prostate adenocarcinoma is proven. 2) Patient should receive MRI examination before treatment. 3) cT1-T2N0M0, Gleason score<or=7, pretreatment PSA <20ng/ml 4) ECOG PS 0-1 5) Patients must sign informed consent form prior to registration
Exclusion criteria
Exclusion criteria: 1) Prior pelvic radiotherapy 2) Small cell carcinoma 3) cT3-4, exist of metastasis 4) Prior prostatectomy 5) Concurrent invasive cancers or collagen disease 6) PSA failure following hormonal therapy 7) If the attending physician judges the case inappropriate. 8) Gold allergy 9) Severe diabetes mellitus 10) Usage of anticoagulants/antiaggregant 11) Biochemical failure after hormonal therapy 12) Difficult to comply with dose constraints 13) IPSS>or=20
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 5-y biochemical relapse free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| 5-y distant metastasis free survival 5-y cause-specific survival 5-y overall survival Toxicity (acute and late) | — |
Countries
Japan
Contacts
Public ContactKen Takeda
Tohoku University Hospital Department of Radiation Oncology
Outcome results
None listed